journal
MENU ▼
Read by QxMD icon Read
search

CNS Spectrums

journal
https://www.readbyqxmd.com/read/30198479/neuronal-underpinnings-of-cognitive-impairment-and-improvement-in-mood-disorders
#1
Kamilla W Miskowiak, Cecilia S Petersen
Neuropsychiatric illnesses including mood disorders are accompanied by cognitive impairment, which impairs work capacity and quality of life. However, there is a lack of treatment options that would lead to solid and lasting improvement of cognition. This is partially due to the absence of valid and reliable neurocircuitry-based biomarkers for pro-cognitive effects. This systematic review therefore examined the most consistent neural underpinnings of cognitive impairment and cognitive improvement in unipolar and bipolar disorders...
September 10, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/30198457/dysphagia-characteristics-in-huntington-s-disease-patients-insights-from-the-fiberoptic-endoscopic-evaluation-of-swallowing-and-the-swallowing-disturbances-questionnaire
#2
Yael Manor, Yael Oestreicher-Kedem, Alona Gad, Jennifer Zitser, Achinoam Faust-Socher, Dina Shpunt, Stav Naor, Noit Inbar, Meir Kestenbaum, Nir Giladi, Tanya Gurevich
BACKGROUND: Huntington's disease (HD) is a neurodegenerative disease characterized by increasing dysphagia as the disease progresses. Specific characteristics of the HD dysphagia are not well defined. OBJECTIVE: To characterize the swallowing disturbances of HD patients, to evaluate the feasibility of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in assessing dysphagia in HD patients, and to discern the relation between FEES findings and patients' self-report on dysphagia symptoms and swallowing related quality of life (SWAL-QOL)...
September 10, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/30109845/long-term-safety-and-tolerability-of-aripiprazole-lauroxil-in-patients-with-schizophrenia
#3
Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weiden
OBJECTIVE: Safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia. METHODS: This was an international, multicenter, phase 3, 52-week safety study of 2 fixed doses of AL (441 mg or 882 mg intramuscular every 4 weeks). Safety endpoints included adverse events (AEs) and extrapyramidal symptoms (EPS) including akathisia, injection-site reactions (ISRs), and clinically relevant changes in metabolic and endocrine values...
August 15, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/30086812/lamotrigine-induced-obsessive-compulsive-disorder-in-patients-with-bipolar-disorder
#4
Verinder Sharma, Minakshi Doobay
IntroductionLamotrigine is a commonly used drug in the treatment of bipolar disorder. Although there are reports of its effectiveness in the management of bipolar disorder and comorbid obsessive-compulsive disorder (OCD), lamotrigine has also been associated with obsessionality in patients with bipolar disorder. METHODS: Charts of 8 patients with bipolar disorder who had de novo onset of obsessions and compulsions after the use of lamotrigine were reviewed. The Naranjo scale was used to assess the likelihood of patients developing OCD due to lamotrigine use...
August 8, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/30032737/psychiatric-behavioral-and-cognitive-disorders-in-patients-with-extracranial-cancers
#5
Gabriella Pravettoni, Bernardo Dell'Osso, Tommaso Bocci, Francesca Cortese, Roberta Ferrucci, Valentina Lampis, Chiara Rosci, Alberto Priori
Patients with cancer may report neuropsychiatric abnormalities including cognitive impairment, behavioral disturbances, and psychiatric disorders that potentially worsen their quality of life, reduce their treatment response, and aggravate their overall prognosis. Neuropsychiatric disturbances have a different pathophysiology, including immuno-inflammatory and neuroendocrine mechanisms, as a consequence of oncologic treatments (chemo- and radio-therapy). Among clinicians involved in the management of such patients, psychiatrists need to pay particular attention in recognizing behavioral disturbances that arise in oncologic patients, and determining those that may be effectively treated with psychotropic medications, psychotherapeutic interventions, and an integration of them...
July 23, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29941057/switching-stable-patients-with-schizophrenia-from-their-oral-antipsychotics-to-aripiprazole-lauroxil-a-post-hoc-safety-analysis-of-the-initial-12-week-crossover-period
#6
Peter J Weiden, Yangchun Du, Chih-Chin Liu, Arielle D Stanford
OBJECTIVE: Switching antipsychotic medications is common in patients with schizophrenia who are experiencing persistent symptoms or tolerability issues associated with their current drug regimen. This analysis assessed the safety of switching from an oral antipsychotic to the long-acting injectable antipsychotic aripiprazole lauroxil (AL). METHODS: This was a post hoc analysis of outpatients with schizophrenia who were prescribed an oral antipsychotic and who enrolled in an international, open-label, long-term (52-week) safety study of AL...
June 26, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/30160230/comparing-pharmacologic-mechanism-of-action-for-the-vesicular-monoamine-transporter-2-vmat2-inhibitors-valbenazine-and-deutetrabenazine-in-treating-tardive-dyskinesia-does-one-have-advantages-over-the-other
#7
Stephen M Stahl
The two approved treatments for tardive dyskinesia both inhibit the vesicular monoamine transporter type 2 (VMAT2) yet have pharmacologic properties that distinguish one from the other. Knowing these differences may help optimize which treatment to select for individual patients.
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28870274/psychopharmacological-options-for-adult-patients-with-anorexia-nervosa-the-patients-and-carers-perspectives
#8
Hubertus Himmerich, Moradeke Joaquim, Jessica Bentley, Carol Kan, Julia Dornik, Janet Treasure, Ulrike Schmidt
No abstract text is available yet for this article.
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28847342/availability-of-dopamine-transporters-and-auditory-p300-abnormalities-in-adults-with-attention-deficit-hyperactivity-disorder-preliminary-results
#9
Ching-Lin Chu, I Hui Lee, Mei Hung Chi, Kao Chin Chen, Po See Chen, Wei Jen Yao, Nan Tsing Chiu, Yen Kuang Yang
OBJECTIVE: Previous studies have indicated that there is dopamine transporter (DAT) dysregulation and P300 abnormality in adults with attention-deficit hyperactivity disorder (ADHD); however, the correlations among the three have not been fully explored. METHODS: A total of 11 adults (9 males and 2 females) with ADHD and 11 age-, sex-, and education-level-matched controls were recruited. We explored differences in DAT availability using single-photon emission computed tomography and P300 wave of event-related potentials between the two groups...
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28659221/qtc-interval-in-patients-with-schizophrenia-receiving-antipsychotic-treatment-as-monotherapy-or-polypharmacy
#10
Anja Elliott, Thibault Johan Mørk, Mikkel Højlund, Thomas Christensen, Rasmus Jeppesen, Nikolaj Madsen, Anne Grethe Viuff, Peter Hjorth, Jens Cosedis Nielsen, Povl Munk-Jørgensen
OBJECTIVE: Antipsychotics are associated with a polymorphic ventricular tachycardia, torsades de pointes, which, in the worst case, can lead to sudden cardiac death. The QT interval corrected for heart rate (QTc) is used as a clinical proxy for torsades de pointes. The QTc interval can be prolonged by antipsychotic monotherapy, but it is unknown if the QTc interval is prolonged further with antipsychotic polypharmaceutical treatment. Therefore, this study investigated the associations between QTc interval and antipsychotic monotherapy and antipsychotic polypharmaceutical treatment in schizophrenia, and measured the frequency of QTc prolongation among patients...
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28631584/clinical-characterization-of-italian-suicide-attempters-with-bipolar-disorder
#11
Bernardo Dell'Osso, Matteo Vismara, Cristina Dobrea, Laura Cremaschi, Benedetta Grancini, Chiara Arici, Beatrice Benatti, Massimiliano Buoli, Terence A Ketter, A Carlo Altamura
IntroductionBipolar disorder (BD) is a chronic, highly disabling condition associated with psychiatric/medical comorbidity and substantive morbidity, mortality, and suicide risks. In prior reports, varying parameters have been associated with suicide risk. OBJECTIVES: To evaluate sociodemographic and clinical variables characterizing Italian individuals with BD with versus without prior suicide attempt (PSA). METHODS: A sample of 362 Italian patients categorized as BD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM IV-TR) was assessed and divided in 2 subgroups: with and without PSA...
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28625204/effect-of-aripiprazole-lauroxil-in-patients-with-acute-schizophrenia-as-assessed-by-the-positive-and-negative-syndrome-scale-supportive-analyses-from-a-phase-3-study
#12
Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverman
OBJECTIVE: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. Here, we present exploratory analyses of supportive efficacy endpoints. METHODS: Patients experiencing an acute exacerbation of schizophrenia received AL 441 mg intramuscularly (IM), AL 882 mg IM, or matching placebo IM monthly. Supportive endpoints included changes from baseline at subsequent time points in Clinical Global Impression-Severity (CGI-S) scale score; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive, Negative, and General Psychopathology subscale scores; PANSS Marder factors (post hoc); and PANSS responder rate...
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28535835/a-biopsychosocial-evaluation-of-the-risk-for-suicide-in-schizophrenia
#13
Nuwan C Hettige, Ali Bani-Fatemi, Isaac Sakinofsky, Vincenzo De Luca
The risk of suicide is greatly increased in individuals with schizophrenia. Previous research has identified several potential risk factors for suicidal behavior in schizophrenia, although their ability to independently predict suicide is limited. The objective of this review was to systematically analyze and identify the interaction between the proposed risk factors in the literature that may predict suicidal behavior in schizophrenia. Articles that explored suicidal behavior and suicide risk in schizophrenia that were published between 1980 and August of 2015, indexed in PubMed, MEDLINE, and Scopus were systematically reviewed...
August 2018: CNS Spectrums
https://www.readbyqxmd.com/read/28209212/optimization-of-acute-stroke-care-in-the-emergency-department-a-call-for-better-utilization-of-healthcare-resources-amid-growing-shortage-of-neurologists-in-the-united-states
#14
https://www.readbyqxmd.com/read/29880074/efficacy-of-vortioxetine-in-working-patients-with-generalized-anxiety-disorder-erratum
#15
Michael Cronquist Christensen, Henrik Loft, Ioana Florea, Roger S McIntyre
No abstract text is available yet for this article.
June 8, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29866212/factors-associated-with-poor-satisfaction-with-treatment-and-trial-discontinuation-in-chronic-schizophrenia
#16
Joep H Schoemaker, Ad J J M Vingerhoets, Robin A Emsley
IntroductionDespite consistently high discontinuation rates due to withdrawal of consent (WOC) and insufficient therapeutic effect (ITE) in schizophrenia trials, insight into the underlying factors contributing to poor satisfaction with treatment and dropout is limited. A better understanding of these factors could help to improve trial design and completion rates. METHODS: Using data from 1,136 trial participants with schizophrenia or schizoaffective disorder, we explored associations between predictor variables with (1) dropout due to WOC and ITE and (2) satisfaction with treatment among patients and investigators by means of hierarchic multiple regression analyses...
June 5, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29866209/pharmacotherapy-of-schizophrenia-toward-a-metabolomic-based-approach
#17
Haythum O Tayeb, Hussam A Murad, Misbahuddin M Rafeeq, Frank I Tarazi
Approximately 20%-30% of schizophrenia patients are resistant to current standard pharmacotherapies. Recent schizophrenia research aims to identify specific pathophysiological abnormalities and novel targets in the disease, with the goals of identifying at-risk individuals, facilitating diagnosis, prompting early and personalized interventions, and helping predict response to treatment. Metabolomics involves the systematic study of the profile of biochemical alterations early in the course of a given disorder...
June 5, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29860948/impulsivity-and-decision-making-in-obsessive-compulsive-disorder-after-effective-deep-brain-stimulation-or-treatment-as-usual
#18
Giacomo Grassi, Martijn Figee, Pieter Ooms, Lorenzo Righi, Takashi Nakamae, Stefano Pallanti, Rick Schuurman, Damiaan Denys
OBJECTIVE: Impulsivity and impaired decision-making have been proposed as obsessive-compulsive disorder (OCD) endophenotypes, running in OCD and their healthy relatives independently of symptom severity and medication status. Deep brain stimulation (DBS) targeting the ventral limb of the internal capsule (vALIC) and the nucleus accumbens (Nacc) is an effective treatment strategy for treatment-refractory OCD. The effectiveness of vALIC-DBS for OCD has been linked to its effects on a frontostriatal network that is also implicated in reward, impulse control, and decision-making...
June 4, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29954475/beyond-the-dopamine-hypothesis-of-schizophrenia-to-three-neural-networks-of-psychosis-dopamine-serotonin-and-glutamate
#19
Stephen M Stahl
Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well.
June 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29789033/the-neurological-examination-adapted-for-neuropsychiatry
#20
Sheldon Benjamin, Margo D Lauterbach
The neuropsychiatric examination includes standard neurological and cognitive examination techniques with several additional observations and tasks designed to capture abnormalities common among patients with neuropsychiatric disorders or neurocognitive complaints. Although useful as a screening tool, a single standardized rating scale such as the Mini Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) is insufficient to establish a neuropsychiatric diagnosis. Extra attention is paid to findings commonly seen in the setting of psychiatric disorders, dementias, movement disorders, or dysfunction of cortical or subcortical structures...
June 2018: CNS Spectrums
journal
journal
32687
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"